Fidelity Investments
OBIO icon

Fidelity Investments’s Orchestra BioMed OBIO Stock Holding History

Fidelity Investments’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.8K Buy
+18,076
New +$77K ﹤0.01% 3913
2025
Q3 		– Sell
-1,646
Closed -$4.41K – 5516
2025
Q2 		$4.41K Buy
1,646
+550
+50% +$1.6K ﹤0.01% 4735
2025
Q1 		$4.69K Buy
1,096
+89
+9% +$442 ﹤0.01% 4725
2024
Q4 		$4.03K Sell
1,007
-1,868
-65% -$10K ﹤0.01% 4709
2024
Q3 		$14.8K Buy
2,875
+2,419
+530% +$15.8K ﹤0.01% 4301
2024
Q2 		$3.72K Sell
456
-346
-43% -$2K ﹤0.01% 4622
2024
Q1 		$4.23K Sell
802
-2,547
-76% -$17.3K ﹤0.01% 4555
2023
Q4 		$30.6K Buy
3,349
+1,083
+48% +$7.39K ﹤0.01% 3741
2023
Q3 		$19.8K Buy
2,266
+1,889
+501% +$12.7K ﹤0.01% 3807
2023
Q2 		$2.64K Buy
+377
New +$5.72K ﹤0.01% 4524

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments's OBIO Position: Q1 2026 in Review

Fidelity Investments opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 18,076 shares worth $76.8K. The stake represents ﹤0.01% of the portfolio and ranks #3913 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in OBIO as recently as Q2 2025.

Fidelity Investments first reported a position in OBIO in Q2 2023 and has held it in 10 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Fidelity Investments held 18,076 shares of Orchestra BioMed worth $76.8K as of Q1 2026.
  • Orchestra BioMed was a new Fidelity Investments position in Q1 2026.
  • Orchestra BioMed made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3913 holding.
  • Fidelity Investments first reported a position in Orchestra BioMed in Q2 2023 and has held it in 10 quarters since.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.